Lindsey Wilson, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 416 3rd Ave, Havre, MT 59501 Phone: 406-265-1231 |
Douglas Arthur Safley, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: 416 3rd Ave, Havre, MT 59501 Phone: 406-265-1231 Fax: 406-265-1603 |
Dr. Erica J Farmer, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 20 13th St W, Box 1231, Havre, MT 59501 Phone: 406-262-2020 Fax: 406-262-1655 |
Gary Stremcha, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 416 3rd Ave, Havre, MT 59501 Phone: 406-265-1231 Fax: 406-265-1603 |
Northern Montana Vision Center Optometrist Medicare: Not Enrolled in Medicare Practice Location: 20 13th St W, Havre, MT 59501 Phone: 406-262-2020 |
Havre Optometric Clinic, Pllp Optometrist Medicare: Medicare Enrolled Practice Location: 416 3rd Ave, Havre, MT 59501 Phone: 406-265-1231 Fax: 406-265-1603 |
News Archive
Patrick Wilson, PhD, professor of medicine and rheumatology at the University of Chicago, and a group of researchers from three other institutions have received a Grand Challenge for Universal Influenza Vaccine Development grant – a $12 million initiative funded by the Bill & Melinda Gates Foundation and Flu Lab.
ETH Zurich professor Peter Seeberger has been working on a sugar-based malaria vaccine for years.
Two biomarkers widely being investigated as predictors of heart and vascular disease appear to indicate risk for "silent" strokes and other causes of mild brain damage that present no symptoms, report researchers from The Methodist Hospital and several other institutions in an upcoming issue of Stroke (now online).
There is no evidence that probiotics are effective in treating acute infectious diarrhoea, state the authors of this Cochrane review update. Previous editions of the review had suggested they were; but a review update of the evidence, which included new trials, has overturned the review's previous findings.
NovaBay Pharmaceuticals, Inc. today announced that its Aganocide® compounds demonstrate potent antifungal activity in an established pre-clinical infected nail model of onychomycosis. The study data will be presented tomorrow at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Philadelphia.
› Verified 8 days ago